Genentech recalls psoriasis drug Raptiva

by Michael J. Evans on April 9, 2009

in Consumer Protection,Dangerous Products

The FDA announced yesterday that Genentech was withdrawing the psoriasis drug Raptiva because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system.  There is no known effective treatment for PML. About 2,000 people in the U.S. are believed to be taking the drug.

Share

Comments on this entry are closed.

Previous post:

Next post: